IL118103A - Composition of thymus factor protein comprising a lysine-rich histone factor capable of precipitating beta-, alpha1-, alpha2-macroglobulins of a healthy mammal - Google Patents

Composition of thymus factor protein comprising a lysine-rich histone factor capable of precipitating beta-, alpha1-, alpha2-macroglobulins of a healthy mammal

Info

Publication number
IL118103A
IL118103A IL11810396A IL11810396A IL118103A IL 118103 A IL118103 A IL 118103A IL 11810396 A IL11810396 A IL 11810396A IL 11810396 A IL11810396 A IL 11810396A IL 118103 A IL118103 A IL 118103A
Authority
IL
Israel
Prior art keywords
macroglobulins
alpha1
alpha2
lysine
factor
Prior art date
Application number
IL11810396A
Other languages
English (en)
Other versions
IL118103A0 (en
Original Assignee
Tomson U S A Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tomson U S A Ltd filed Critical Tomson U S A Ltd
Publication of IL118103A0 publication Critical patent/IL118103A0/xx
Publication of IL118103A publication Critical patent/IL118103A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL11810396A 1995-05-01 1996-05-01 Composition of thymus factor protein comprising a lysine-rich histone factor capable of precipitating beta-, alpha1-, alpha2-macroglobulins of a healthy mammal IL118103A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43188395A 1995-05-01 1995-05-01
US48554895A 1995-06-07 1995-06-07
US64193696A 1996-05-01 1996-05-01

Publications (2)

Publication Number Publication Date
IL118103A0 IL118103A0 (en) 1997-03-18
IL118103A true IL118103A (en) 2000-02-29

Family

ID=27411755

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11810396A IL118103A (en) 1995-05-01 1996-05-01 Composition of thymus factor protein comprising a lysine-rich histone factor capable of precipitating beta-, alpha1-, alpha2-macroglobulins of a healthy mammal

Country Status (10)

Country Link
EP (2) EP0826003B1 (fr)
CN (1) CN1221568C (fr)
AT (1) ATE205221T1 (fr)
BG (1) BG64056B1 (fr)
CA (1) CA2220347C (fr)
DE (1) DE69615015T2 (fr)
DK (1) DK0826003T3 (fr)
EA (1) EA001100B1 (fr)
ES (1) ES2163028T3 (fr)
IL (1) IL118103A (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008057479A1 (de) 2008-11-14 2010-05-20 Bernhard, Stefan, Dr. Vorrichtung und Verfahren zur Stärkung des Immunsystems durch Langzeitstimulation der Thymusdrüse
CN112782398A (zh) * 2020-12-28 2021-05-11 重庆生命知源科技有限公司 一种微量蛋白免疫印迹检测方法
CN119746205B (zh) * 2024-12-25 2025-09-30 深圳市浩然盈科通讯科技有限公司 一种智能输液控制方法、系统、存储介质及程序产品

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415553A (en) * 1973-08-06 1983-11-15 Dso "Pharmachim" Compositions, processes for their preparation and method for treatment of neoplasms
WO1985003003A1 (fr) * 1984-01-12 1985-07-18 Volker Rusch Substance biologiquement active avec des proprietes hormonales, son procede de fabrication et utilisation d'histones a des fins medicales
AU2800389A (en) * 1987-12-02 1989-07-05 Regents Of The University Of California, The Aids-related anti-t-cell antibody test
GB9209874D0 (en) * 1992-05-07 1992-06-24 Ml Lab Plc Pharmaceutical compositions

Also Published As

Publication number Publication date
DE69615015D1 (de) 2001-10-11
BG102083A (en) 1998-10-30
ATE205221T1 (de) 2001-09-15
EP0826003B1 (fr) 2001-09-05
DK0826003T3 (da) 2001-11-26
BG64056B1 (bg) 2003-11-28
CA2220347A1 (fr) 1996-11-07
EP1104770A3 (fr) 2001-06-27
DE69615015T2 (de) 2002-06-27
CN1189839A (zh) 1998-08-05
IL118103A0 (en) 1997-03-18
ES2163028T3 (es) 2002-01-16
EA199700353A1 (ru) 1998-04-30
HK1009457A1 (en) 1999-06-04
EP1104770A2 (fr) 2001-06-06
CA2220347C (fr) 2003-03-18
EA001100B1 (ru) 2000-10-30
EP0826003A1 (fr) 1998-03-04
CN1221568C (zh) 2005-10-05

Similar Documents

Publication Publication Date Title
EA200000596A1 (ru) Tat вич-1 или его производные для профилактической и лечебной вакцинации
CA2596274A1 (fr) Virus mva recombinants et leur utilisation
RU94002475A (ru) Фармацевтическая композиция и ее применение для лечения вирусных инфекций
NO20025153L (no) Fremgangsmåter og sammensetninger for å påvirke formering av HIV-1, HIV-2 og SIV
WO2002068654A3 (fr) Poxvirus recombine pour proteines chimeres du virus de l'immunodeficience humaine
WO2002014362A3 (fr) Gene de fusion non structurel ns3/4a du virus de l'hepatite c
IL115074A0 (en) A novel salt of (1s,4r)-cis-4--Ú2-amino-6-(cyclopropylamino)-9h-purin-9-yl-¾- 2-cyclopentene-1-methanol solvates thereof their preparation and pharmaceutical compositions containing them
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
WO2005052159A8 (fr) Homologue d'interleukine-10 et ses utilisations
IL118103A (en) Composition of thymus factor protein comprising a lysine-rich histone factor capable of precipitating beta-, alpha1-, alpha2-macroglobulins of a healthy mammal
CA2181590A1 (fr) Peptomeres a immunogenicite accrue
EP0719281B1 (fr) Constructions de peptides a branches multiples destines a etre utilises contre le vih
US5622933A (en) Multiple branch peptide constructions for use against HIV
BR9608837A (pt) "composição obtida de células para detectar uma infecção por vìrus da imunodeficiência humana, aparelho, kit e métodos para sua detecção, purificação da proteìna e sua obtenção e tratamento do ser humano"
CA2057612A1 (fr) Peptides selectionnes de l'antigene specifique au groupe (gag) du virus de l'immunodeficience humaine (vih), sa preparation et son utilisation
IL102815A (en) Pharmaceutical compositions for the treatment of infection caused by the human immunodeficiency virus
DE69922642D1 (de) Virale chimären aus caev und hiv-1 genetischen elementen
CA2171531C (fr) Constructions peptidiques a ramifications multiples, utiles contre le vih
WO1991018618A3 (fr) Compositions immunotherapeutiques de traitement et de prevention d'infections dues au sida, au para-sida et au vih
WO2002026253A1 (fr) Vaccin contre le sida, son procede de preparation et ses applications
EP0323424A3 (fr) Peptides correspondant à HIV-env 583-599, leurs analogues et utilisation de ces peptides
KR20040000401A (ko) Ｈｉｖ 바이러스에 대한 천연 항체
JP3725899B6 (ja) Ｈｉｖに対して使用するための多分岐ペプチド構築物
WO2002068464A3 (fr) Proteine hybride utilisee pour bloquer la proteine nef du vih
ES2021943A6 (es) Procedimiento para la sintesis de peptidos para neutralizar la infectividad del virus del sida (vhs)

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees